New treatment for dizziness in people with multiple sclerosis
Daily Versus Intermittent Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
This study tests a new treatment using a special technology to see if personalized eye exercises can help reduce dizziness for people with multiple sclerosis.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 138 (estimated) |
| Ages | 18 Years to 89 Years |
| Sex | All |
| Sponsor | Emory University Academic / other |
| Drugs / interventions | Immunotherapy |
| Locations | 1 site (Atlanta, Georgia) |
| Trial ID | NCT06495138 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of a novel treatment aimed at alleviating dizziness in individuals with multiple sclerosis (MS). It compares daily personalized gaze stabilization training to intermittent gaze stability training to determine which is more effective. The intervention utilizes a technology called StableEyes, designed to enhance gaze stability through a gradual approach to vestibular exercises. By targeting the vestibulo-ocular reflex, the study aims to improve vision stability and reduce dizziness, ultimately enhancing the quality of life for participants.
Who should consider this trial
Good fit: Ideal candidates include individuals with a confirmed diagnosis of primary progressive or relapsing-remitting MS who experience dizziness and have a history of falls.
Not a fit: Patients with clinically isolated syndrome, significant cognitive impairment, or certain ocular conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce dizziness and improve daily functioning for patients with multiple sclerosis.
How similar studies have performed: Preliminary research has shown promising results for similar approaches, suggesting potential effectiveness for this novel treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Neurologist-confirmed diagnosis of primary progressive or relapsing and remitting MS per The 2017 Revision of the McDonald Criteria and the Magnetic Resonance Imaging in MS, or a healthy volunteer without a diagnosis of multiple sclerosis or any related neurological conditions * Fluent in speaking and understanding English * Subjects with multiple sclerosis have self-reported vestibular symptoms of dizziness, imbalance, and/or a history of at least two falls in the prior 12 months Exclusion Criteria: * Clinically isolated syndrome or radiologically isolated syndrome. * Worsening MS symptoms during the prior 60 days * Immunotherapy change in the prior 60 days * Self-reported cognitive impairment that limits independence with basic and instrumental activities of daily living * Systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 90 mmHg at rest * Static visual acuity with correction of worse than 1.0 logMAR * Manifest ocular misalignment ≥ 5 diopters (e.g., tropia, lazy eye, strabismus} * Convergence insufficiency * Intra-nuclear ophthalmoplegia * Vestibular Migraine * Major orthopedic conditions that limit cervical spine range of motion or that alter walking * Self-reported current or potential for pregnancy during enrollment * Ongoing participation in vestibular rehabilitation for dizziness
Where this trial is running
Atlanta, Georgia
- Emory Univeristy — Atlanta, Georgia, United States (Recruiting)
Study contacts
- Principal investigator: Colin Grove, PT, MS, DPT, PhD — Emory University
- Study coordinator: Colin Grove, PT, DPT, MS, PhD
- Email: colin.r.grove@emory.edu
- Phone: (404) 712-8685
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.